ICLR vs. REGN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ICLR and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ICLR | REGN |
|---|---|---|
| Company Name | ICON Public Limited Company | Regeneron Pharmaceuticals, Inc. |
| Country | Ireland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 12.41 billion USD | 74.98 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | May 15, 1998 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ICLR and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ICLR | REGN |
|---|---|---|
| 5-Day Price Return | 2.85% | 5.92% |
| 13-Week Price Return | -7.77% | 19.48% |
| 26-Week Price Return | 15.44% | 20.79% |
| 52-Week Price Return | -20.46% | -13.78% |
| Month-to-Date Return | -5.61% | 6.40% |
| Year-to-Date Return | -22.66% | -2.64% |
| 10-Day Avg. Volume | 0.64M | 0.97M |
| 3-Month Avg. Volume | 1.15M | 1.03M |
| 3-Month Volatility | 42.52% | 37.82% |
| Beta | 1.28 | 0.39 |
Profitability
Return on Equity (TTM)
ICLR
6.32%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
ICLR’s Return on Equity of 6.32% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
REGN
15.31%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.31% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
ICLR
7.40%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
ICLR’s Net Profit Margin of 7.40% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
REGN
32.13%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 32.13% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ICLR
10.03%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
ICLR’s Operating Profit Margin of 10.03% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
REGN
25.89%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 25.89% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ICLR | REGN |
|---|---|---|
| Return on Equity (TTM) | 6.32% | 15.31% |
| Return on Assets (TTM) | 3.59% | 11.91% |
| Net Profit Margin (TTM) | 7.40% | 32.13% |
| Operating Profit Margin (TTM) | 10.03% | 25.89% |
| Gross Profit Margin (TTM) | 28.15% | 86.28% |
Financial Strength
Current Ratio (MRQ)
ICLR
1.06
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
ICLR’s Current Ratio of 1.06 falls into the lower quartile for the Life Sciences Tools & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
REGN
4.06
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
REGN’s Current Ratio of 4.06 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ICLR
0.37
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
ICLR’s Debt-to-Equity Ratio of 0.37 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
REGN
0.09
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ICLR
4.80
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
ICLR’s Interest Coverage Ratio of 4.80 is positioned comfortably within the norm for the Life Sciences Tools & Services industry, indicating a standard and healthy capacity to cover its interest payments.
REGN
49.98
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
REGN’s Interest Coverage Ratio of 49.98 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ICLR | REGN |
|---|---|---|
| Current Ratio (MRQ) | 1.06 | 4.06 |
| Quick Ratio (MRQ) | 1.02 | 3.38 |
| Debt-to-Equity Ratio (MRQ) | 0.37 | 0.09 |
| Interest Coverage Ratio (TTM) | 4.80 | 49.98 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ICLR
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
ICLR currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ICLR
0.00%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
ICLR has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
REGN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ICLR | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ICLR
20.85
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
In the lower quartile for the Life Sciences Tools & Services industry, ICLR’s P/E Ratio of 20.85 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
REGN
15.92
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
REGN’s P/E Ratio of 15.92 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ICLR
1.54
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
In the lower quartile for the Life Sciences Tools & Services industry, ICLR’s P/S Ratio of 1.54 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
REGN
5.12
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
REGN’s P/S Ratio of 5.12 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ICLR
1.46
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
ICLR’s P/B Ratio of 1.46 is in the lower quartile for the Life Sciences Tools & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
REGN
1.93
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
REGN’s P/B Ratio of 1.93 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | ICLR | REGN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.85 | 15.92 |
| Price-to-Sales Ratio (TTM) | 1.54 | 5.12 |
| Price-to-Book Ratio (MRQ) | 1.46 | 1.93 |
| Price-to-Free Cash Flow Ratio (TTM) | 12.96 | 18.78 |